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HIGHLIGHTS  
  
• cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a feasible and 
safe procedure for treatment of Peritoneal surface malignancies.  
• Multidisciplinary evaluation of the patient is mandatory to obtain positive results.   
• Cases of CRS and HIPEC in children are few, therefore it’s important to share every cases with the 
surgical and oncological community  
• In well selected cases, both disease free survival and overall survival are improved  
  
  
ABSTRACT  
Introduction:  
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is nowadays a feasible 
and effective treatment for peritoneal metastasis. We present a case of a 14 years old child with peritoneal 
metastasis from recurrent colorectal cancer.  
Presentation of case:  
Colonoscopy and CT-scan were performed leading to the diagnosis of a stenosing adenocarcinoma of the 
right colon in 2015. Two pelvic lesions were found at the total body PET scan, suspected for peritoneal 
metastasis. Neoadjuvant chemotherapy was administered, and restaging CT-scan and magnetic resonance 
(MRI) highlighted a partial response. The patient underwent right laparoscopic hemicolectomy. The 
postoperative staging was T4 N1 G3. Seven months after the last cycle of adjuvant chemotherapy, CT-scan 
revealed two huge abdominal masses. The patient underwent explorative laparotomy and bilateral 
oophorectomy, positive for metastasis from colorectal cancer and peritoneal washing cytology was positive 
for neoplastic cells. A CT-scan was performed on December 2017 showed a suspect lesion below the anterior 
abdominal wall. The case was discussed at the tumour board and the indication for CRS and HIPEC was given. 
In January 2018 the child underwent complete CRS and HIPEC with no complications. No adjuvant 
chemotherapy was administered. After 11 months the follow up is negative for the recurrent disease.  
Discussion and Conclusion  
Cytoreduction and HIPEC can be performed even in children as a feasible and safe treatment with successful 
outcomes. As for adults, an appropriate multidisciplinary pre-operative work up and a correct cases selection 
is needed to have the best results even regarding the quality of life.  
INTRODUCTION  
Cytoreductive surgery [CRS] combined with hyperthermic peritoneal perfusion with chemotherapy [HIPEC] is 
nowadays a well-established treatment in patients with peritoneal surface malignancies without 
extraperitoneal disease. [2,3] Therefore the patients are considered eligible for CRS and HIPEC if they have 
got a good performance status and don’t have all contraindications for large general surgery.  CRS is 
performed doing a complete resection of all tumoral lesions and invaded organs. Extensive peritonectomy is 
always performed, and before the administration of HIPEC, all the anastomosis are done. HIPEC is performed 
by perfusion of high-temperature chemotherapy molecules such as Mitomycin C, Doxorubicin or Cisplatin. 
The synergy of the two techniques provides long-term disease control, and it is recognised as the first-choice 
treatment for Pseudomyxoma peritoneii and Peritoneal mesothelioma. [4,5] CRS and HIPEC find very specific 
indications in well-selected patients with peritoneal carcinomatosis from colorectal, ovarian and gastric 
cancer in adults.  
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Among the pediatric population, the use of HIPEC remains debated. Desmoplastic small round cell tumour 
[DSRCT] has been the first main indication in children and, according to the recent literature, few other 
tumours have been treated with CRS and HIPEC including colorectal cancer.[6] We present a case of CRS and 
HIPEC in a 14 years old patient with peritoneal carcinomatosis from adenocarcinoma of the right colon. Only 
other four pediatric cases of peritoneal metastasis from colon cancer treated by CRS and HIPEC have been 
described in literature up to now.  
PRESENTATION OF CASE  
A 12 years old girl presented to the emergency department in 2015 for hematochezia and anaemia, and she 
was admitted to the pediatric ward. The patient underwent to colonoscopy with the evidence of an 
obstructive and ulcerated lesion of the right colon affecting the caecum and the ascending colon. Multiple 
biopsies were performed, and the histological examination highlighted an infiltrating adenocarcinoma of the 
right colon, CK20+, CDK 7+. A staging CT-scan of thorax and abdomen confirmed the presence of an 8 cm 
partially obstructing lesion of the right colon, moreover, two small pelvic nodules were found. The PET-CT 
scan confirmed the suspect of peritoneal carcinomatosis of the pelvis and the patient underwent two cycles 
of chemotherapy with FOLFOXIRI. At the re-staging CT-scan and MRI, the primitive tumour showed a partial 
response to the chemotherapy, while the two pelvic nodules were no more detectable. After discussion with 
oncologists and paediatricians, the patient underwent laparoscopic right hemicolectomy. At the pathological 
examination, the diagnosis of signet ring colon carcinoma was confirmed. A tumour presented nerve and 
blood vessel invasion and 3 out of 57 lymph nodes resected were found positive as secondary localisation. 
The post-operative staging resulted in T4 N1 M0 G3. The immunohistochemistry showed both KRAS and BRAF 
wild-type. From December 2016 to April 2017 the patient received eight cycles of FOLFOX.   
In November 2017 the patient has admitted in the pediatric ward for abdominal pain and a CT-scan of the 
abdomen highlighted the presence of two bulky pelvic mass both growing from ovaries (Fig.1). The patient 
underwent an exploratory laparotomy with bilateral ovariectomy and peritoneal washing during surgery. 
Both ovaries resulted in the site of metastasis from colon adenocarcinoma at the pathological examination. 
Nonetheless, the peritoneal washing was positive for neoplastic cells. In December 2017 at the control 
CTscan, suspected peritoneal metastasis were found in the contest of the right rectus muscle and of the 
mesentery next to the umbilicus (Fig.2). The case was discussed at the tumour board, and the indication for 
CRS and HIPEC was given.  
In January 2018 the patient underwent CRS and HIPEC. General anaesthesia was induced with Propofol using 
the TIVA-TCI Schnider model [effect-site targeting]; also, Methylprednisolone 3 mg/kg was given as part of 
an internal protocol aimed at reducing cytokine release during major abdominal surgery. Right radial artery 
was cannulated for invasive blood pressure monitoring, and a central line catheter was inserted into the left 
internal jugular vein using an US-guided posterior approach. An epidural catheter was placed in lateral 
decubitus with the median approach, at D12-L1 level. An exploratory laparotomy was performed before to 
proceed with complete peritonectomy, PCI was 3. The nodule on the anterior abdominal wall was resected. 
Complete omentectomy and resection of the round ligament were performed, spleen and gallbladder were 
preserved. At the end of the procedure the CCR was complete (CCR-0) (Fig.3). One-hour prior HIPEC began, 
warming tools were stopped [forced-air devices and fluid warmers], and ice packs on the neck, forehead, and 
armpits were applied. Before to proceed with HIPEC two thoracic drainage were positioned. HIPEC was 
administrated at 42 °C with 57.6 mg of mitomycin C for 60 minutes.  
The immediate postoperative course was managed in the Intensive Care Unit [ICU], with rapid weaning from 
mechanical ventilation. No significant variation in creatinine values or renal function was observed. Rapid 
Lactate clearance occurred. Length of stay in ICU was less than 24 hours.  
Postoperative analgesia management was complicated by pain secondary to chest drainages not covered by 
neuraxial technique, so rescue doses of NSAIDs and Morphine were necessary. The peridural catheter was 
removed during the 7th postoperative day while refeeding occurred on the 6th. The patient was discharged 
on the 14th postoperative day.  
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The pathological examination showed a complete resection of the tumoral nodules. The case has been 
discussed with oncologists; no further chemotherapy was indicated. The patient underwent a CT-scan 
followup every three months.   
At the last CT-scan, eleven months after the procedure, no evidence of recurrence was shown. The patient is 
now in good health with a normal quality of life.  
  
  
  
DISCUSSION  
The first experience with CRS and HIPEC in children with DSRCT was reported in 2007 by Hayes-Jordan, HIPEC 
was administrated with cisplatin for 90 minutes, no postoperative complication occurred. The youngest 
patient treated by HIPEC reported in the literature was three years old, treated for a peritoneal Ewing 
sarcoma. [7] Several studies confirm the feasibility of CRS and HIPEC in children, although, between some 
cohort, high morbidity, up to 66% is reported. [8-9] The major influence on mortality and morbidity can be 
referred to the histologic type of the tumour, numbers of organs involved and PCI [10]. As for adults, even in 
children, regardless of the histology, the completeness of cytoreduction is a critical component in the 
extension of survival. A recent study hypothesised that treating peritoneal malignancies with HIPEC closer 
from initial diagnosis can decrease morbidity significantly in specific neoplasms of the pediatric population.  
[11] Hayes-Jordan reported very few complications attributed to HIPEC. What is evident from his series is 
that severe complications occurred in 28% of the patients as wound infection, small bowel obstruction or 
urinary tract infection. Wound infections were treated with washing and vacuum therapy, and two patients 
required to go under surgery to solve bowel obstruction.  No complications as anastomotic leakage or bone 
marrow suppression were observed. [12]In the early phase of his experience Hayes described 3 cases of renal 
insufficiency secondary to cisplatin. After that, the perioperative hydration protocol was updated, and no 
more renal failure has been found. [13,14] A recent retrospective analysis reported the rate of complications 
in a cohort of 2149 patients treated for peritoneal metastasis from a large variety of tumours. The 19.3% of 
the patient presented a grade III/IV complication. Among these, the 14.3% needed reoperation for fascial 
dehiscence, hemorrhage, bile leak, and anastomotic leak. Pulmonary embolism showed up in 3.4% of 
patients. More rarely but gastric perforation, gastric ulcer and cecal perforation occurred. [15] These results 
are possible when there is a strong collaboration between experienced surgeons, medical oncologists, 
radiation oncologists, anesthesiologists, radiologists, and ancillary surgical specialists combined with solid 
nursing, nutrition and physiotherapy infrastructure.  
CONCLUSIONS  
Selection of the patients and multidisciplinary approach to PSM allow the best results. In pediatric patients, 
the indications for CRS-HIPEC are very rare, mainly for the small incidence of tumour-types that can take 
advantage of the treatment. The only practical way to perform prospective randomised clinical trials is to 
share knowledge creating a large multicenter database as was created by the Peritoneal Surface Oncology 
International [PSOGI] for appendiceal neoplasms, mesothelioma and rare tumours. Meanwhile, reporting 
experience even with a small number of patients is essential.   
  
 Conflicts of interest 
No conflicts of interest. 
Sources of funding 
Non funding were used. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Ethical Approval 
Local ethic committee approval n°247/2016 and EudraCT n°2016-000823-24. 
Consent 
An informed written consent to use data for clinical research and publication was given at the 
hospital admission. 
The authors confirm that the patient’s parents signed the informed written consent to the surgical 
procedure and an explicit permission to use personal details and data. 
Author’s contribution 
Sorrentino Lorena, MD: Data collection and author of case report and discussion. 
Serra Francesco, MD: Review of surgical technique literature and co-author of discussion. 
Cabry Francesca, MD: Review of surgical technique literature and author of introduction. 
De Julis Stefano, MD: Consultant of anesthesiology procedure. 
Barbieri Elisa, MD: Consultant of anesthesiology procedure. 
Girardis Massimo, MD PhD: Consultant of anesthesiology procedure.  
Pier Luca Ceccarelli, MD: Consultant of the pediatric clinical case. 
Gelmini Roberta, MD PhD: Supervisor and co-author of entire manuscript. 
Registration of Research Studies 
The study is registered at AIFA: EudraCT n°2016-000823-24. 
Disclosure statement 
The authors have nothing to disclose. 
Guarantor 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Gelmini Roberta, MD PhD. 
Provenance and peer review 
Not commissioned externally peer reviewed. 
  
REFERENCES  
1. Agha RA, Fowler AJ, Saeta A, et al [2016] The SCARE Statement: Consensus-based surgical case report 
guidelines. Int J Surg Lond Engl 34:180-186 . doi. 10.1016/j.ijsu.2016.08.014  
2. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative 
intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 
1989; 16:83– 97.   
3. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995; 221:29– 42.  
4. Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new 
management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004; 
5:219–228.  
5. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy for malignant peritoneal mesothelioma: a multi-institutional experience. J Clin Oncol. 
2009; 27:6237–6242  
6. Hayes-Jordan A, Anderson P, Curley S, et al. Continuous hyperthermic peritoneal perfusion for 
desmoplastic small round cell tumour. J Pediatr Surg.2007; 42:29–32. 12. Hayes-Jordan A, Green H,  
Lin H, et al.                         
7. Hayes-Jordan A, Lopez C, Green HL, Xiao LC, Huh W, Herzog CE. Cytoreductive surgery [CRS] and 
hyperthermic intraperitoneal chemotherapy [HIPEC] in pediatric ovarian tumours: a novel treatment 
approach. Pediatr Surg Int.2015; 32:71–73.  
8. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive 
surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritoneii. Ann Surg 
Oncol. 2006; 14:484–492.  
9. Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitoneal  chemotherapy 
an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 
procedures.J Surg Oncol.2016;113:796–803  
10. Scalabre A, Glehen O, Sarnacki S et al. Cytoreductive surgery and hyperthermic intraperitoneal 
perfusion with chemotherapy in children with peritoneal tumour spread: A French nationwide study 
over 14 years.Pediatr Blood Cancer. 2018 Apr;65[4]. E pub 2017 Dec 29  
11. Zmora O, Hayes-Jordan A, Bilik R et al. Cytoreductive surgery [CRS] and hyperthermic intraperitoneal 
chemotherapy [HIPEC] for disseminated intraabdominal malignancies in children—a singleinstitution 
experience. J Pediatr Surg. 2018 Jul;53[7]:1381-1386. E pub 2017 Oct 2  
12. Hayes-Jordan A, Anderson P, Curley S, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal 
Chemotherapy [HIPEC] for children, adolescents, and young adults: the first 50 cases. Ann Surg Oncol. 
2015; 22:1726–1732  
13. Hayes-Jordan A, Green H, Ludwig J, Anderson P. Toxicity of hyperthermic intraperitoneal 
chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and 
phase 1 results. Pediatr Blood Cancer.2012;59:395–7.  
14. Green H, Lin H, Owusu-Agyemang P, et al. Perioperative renal protective treatment avoids renal 
toxicity in pediatric and adult patients undergoing HIPEC with cisplatin. J Pediatr Oncol.2014.  
AC
CE
PT
ED
 M
AN
US
CR
IPT
15. Piso P, Pelz J et al. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic 
Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive 
Patients. Ann Surg Oncol. 2019 Jan;26(1):148-154. doi: 10.1245/s10434-018-6992-6. Epub 2018 Nov 
19.  
  
  
  
     
AC
CE
PT
ED
 M
AN
US
CR
IPT
PICTURES  
1. Follow up CT-SCAN of the abdomen that highlight the presence of two bulky pelvic mass both growing 
from ovaries  
  
2. Pre-operative CT-SCAN: peritoneal metastasis were found in the contest of the right rectus muscle 
and of the mesentery next to the umbilicus’’  
  
  
3. Abdominal cavity after CRS plus HIPEC CCR=0  
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